about
Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.Long-acting slow effective release antiretroviral therapy.Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementationA long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.Willingness to use pre-exposure prophylaxis among Black and White men who have sex with men in Atlanta, Georgia.Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections.Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution.Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.Investigational HIV integrase inhibitors in phase I and phase II clinical trials.Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States.Acceptability of Injectable and On-Demand Pre-Exposure Prophylaxis Among an Online Sample of Young Men Who Have Sex with Men in California
P2860
Q30249113-10FD2C47-FF8A-44FE-9DD8-B9026D3ABA43Q36262152-95B1993C-123D-49AE-98E9-5FD564BFD71BQ36296707-A7CFD40A-5DFE-468A-A916-BDDD4AB9019AQ36901505-FA989020-4493-4A9D-9207-E8E75BEDC7C3Q36934918-8F651682-CE4E-469F-BAAB-458CA6DE0202Q38717420-682BE117-5029-4E2F-AF17-43ACE88642B6Q38750666-55407950-3FB2-46B8-BB5C-D20F37BA153AQ39371494-C16F41C6-619F-4099-A12B-E402D37E326AQ40105941-B07B8272-B1B7-449E-9CBA-CB26AFA7D8CFQ47095093-D2519BCE-10B6-4938-8806-D2D8BAE55D4DQ47561586-671CA1D5-7090-4692-B558-5D261C65F241Q47909110-4B594E89-1C2C-4B9F-AA47-3F2ADEB1A870Q49382513-A858E8F0-FCB0-4E95-BFAF-24E37037816AQ57173053-986E36DB-0940-4A48-85DE-7E463BFF0CB6
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cabotegravir long-acting for HIV-1 prevention.
@en
type
label
Cabotegravir long-acting for HIV-1 prevention.
@en
prefLabel
Cabotegravir long-acting for HIV-1 prevention.
@en
P1476
Cabotegravir long-acting for HIV-1 prevention.
@en
P2093
Chasity D Andrews
P304
P356
10.1097/COH.0000000000000161
P577
2015-07-01T00:00:00Z